IBRX Stock: Anktiva's Approvals and What Comes Next

Core Insights - ImmunityBio (IBRX) is transitioning into a commercial-stage immunotherapy developer, with its future closely linked to Anktiva, its primary asset driving revenue and regulatory milestones [2][3] Business Overview - ImmunityBio focuses on immunotherapies that activate both innate and adaptive immune systems, with Anktiva as the lead product and key revenue driver [3][4] - Anktiva is an interleukin-15 receptor superagonist antibody-cytokine fusion protein aimed at stimulating natural killer cells and T cells, positioning it as a versatile immuno-oncology platform [4] Revenue Growth - In 2025, ImmunityBio reported total revenue of $113.3 million, a significant increase from $14.7 million in 2024, primarily driven by Anktiva sales [6][11] - The revenue growth is attributed to the launch timeline, with initial shipments starting in May 2024 following FDA approval in April 2024 [7] Adoption and Market Trends - In Q4 2025, net product sales reached $38.3 million, reflecting a 20% quarter-over-quarter growth, indicating increasing demand as the company enters 2026 [9][11] - Repeat prescribing behavior among physicians is a positive adoption indicator, suggesting sustained ordering patterns as providers gain experience with Anktiva [10] International Expansion - ImmunityBio is expanding its international footprint, with conditional marketing authorization granted in Europe and Saudi Arabia for Anktiva, enhancing commercial opportunities [13][14] - A commercial team led by Accord Healthcare will target 31 European countries, with Germany prioritized for early launches in 2026 [15] Label Expansion Efforts - Label expansion is a critical value driver, with Anktiva showing a 71% complete response rate in a phase II/III study for BCG-unresponsive CIS [16] - The company is also pursuing earlier-line opportunities and plans to file for U.S. approval by the end of 2026 based on interim analysis results [17] Regulatory Developments - A supplemental biologics license application for Anktiva combined with BCG in BCG-unresponsive NMIBC with papillary disease is set for resubmission on March 9 [18]